伴20q缺失的骨髓增生异常综合征:ASXL1染色体缺失与基因突变的发生率、预后价值及对阿扎胞苷反应的影响
该研究纳入153例伴del(20q)的MDS患者,评估ASXL1染色体改变和基因突变的发生率、预后价值及对阿扎胞苷(AZA)反应的影响,并进行HAP1野生型与ASXL1敲除细胞的体外AZA反应实验。ASXL1DEL/ASXL1MUT患者单因素分析与AZA反应更差相关,HAP1KN细胞较HAP1WT对AZA更耐药。
要点
- ASXL1DEL/ASXL1MUT患者单因素分析与AZA反应更差相关,ASXL1敲除细胞对AZA更耐药。
核心结论
- ASXL1改变对伴del(20q)的MDS具有负面预后影响,可能有助于预后风险分层和治疗决策。
研究设计与样本
- 研究纳入153例伴del(20q)的MDS患者,评估ASXL1染色体改变和基因突变的发生率、预后价值及对AZA反应的影响。
- 体外实验检测HAP1野生型(HAP1WT)和HAP1 ASXL1敲除(HAP1KN)细胞对AZA的反应。
主要发现
- ASXL1DEL与更低血小板计数相关。
- 最常见突变基因为U2AF1(16%)、ASXL1(14%)、SF3B1(11%)、TP53(7%)和SRSF2(6%)。
临床怎么用
- 对伴del(20q)的MDS患者可考虑检测ASXL1染色体缺失和基因突变以辅助预后风险分层。
- ASXL1DEL/ASXL1MUT患者可能对AZA反应更差,治疗决策时可参考ASXL1状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In myelodysplastic syndromes (MDS), the 20q deletion [del(20q)] may cause deletion of the ASXL1 gene. We studied 153 patients with MDS and del(20q) to assess the incidence, prognostic value and impact on response to azacitidine (AZA) of ASXL1 chromosomal alterations and genetic mutations. Additionally, in vitro assay of the response to AZA in HAP1 (HAP1WT ) and HAP1 ASXL1 knockout (HAP1KN ) cells was performed. ASXL1 chromosomal alterations were detected in 44 patients (28·5%): 34 patients (22%) with a gene deletion (ASXL1DEL ) and 10 patients (6·5%) with additional gene copies. ASXL1DEL was associated with a lower platelet count. The most frequently mutated genes were U2AF1 (16%), ASXL1 (14%), SF3B1 (11%), TP53 (7%) and SRSF2 (6%). ASXL1 alteration due to chromosomal deletion or genetic mutation (ASXL1DEL /ASXL1MUT ) was linked by multivariable analysis with shorter overall survival [hazard ratio, (HR) 1·84; 95% confidence interval, (CI): 1·11-3·04; P = 0·018] and a higher rate for acute myeloid leukaemia progression (HR 2·47; 95% CI: 1·07-5·70, P = 0·034). ASXL1DEL /ASXL1MUT patients were correlated by univariable analysis with a worse response to AZA. HAP1KN cells showed more resistance to AZA compared to HAP1WT cells. In conclusion, ASXL1 alteration exerts a negative impact on MDS with del(20q) and could become useful for prognostic risk stratification and treatment decisions.
引用
- Martín I, Villamón E, Abellán R, et al. Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations. Br J Haematol. 2021. PMID: 34296432. doi:10.1111/bjh.17675
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。